Followers | 4053 |
Posts | 151245 |
Boards Moderated | 4 |
Alias Born | 08/05/2009 |
Friday, June 05, 2020 8:13:17 AM
On June 4, 2020, Tetraphase Pharmaceuticals, Inc. (the “Company”) received notice that the United States Food and Drug Administration (the “FDA”) approved the Company’s supplemental New Drug application (“sNDA”) for a new strength of XERAVATM (eravacycline) for injection for the treatment of complicated intra-abdominal infections in adult patients containing 100mg of eravacycline per vial as well as an extension of the “in-use” shelf life for XERAVA diluted ready for infusion IV solution from 7 days to 10 days under refrigerated conditions for the existing 50 mg/vial product and for the newly approved 100 mg/vial product.
https://ih.advfn.com/stock-market/NASDAQ/tetraphase-pharmaceuticals-TTPH/stock-news/82607977/current-report-filing-8-k
Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals
https://ih.advfn.com/stock-market/NASDAQ/tetraphase-pharmaceuticals-TTPH/stock-news/82601296/melinta-therapeutics-to-acquire-tetraphase-pharmac
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM